Cargando…
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
BACKGROUND: Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are severa...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025211/ https://www.ncbi.nlm.nih.gov/pubmed/27631393 http://dx.doi.org/10.1371/journal.pone.0162616 |
_version_ | 1782453921355137024 |
---|---|
author | Fukada, Ippei Araki, Kazuhiro Kobayashi, Kokoro Shibayama, Tomoko Takahashi, Shunji Horii, Rie Akiyama, Futoshi Iwase, Takuji Ohno, Shinji Hatake, Kiyohiko Hozumi, Yasuo Sata, Naohiro Ito, Yoshinori |
author_facet | Fukada, Ippei Araki, Kazuhiro Kobayashi, Kokoro Shibayama, Tomoko Takahashi, Shunji Horii, Rie Akiyama, Futoshi Iwase, Takuji Ohno, Shinji Hatake, Kiyohiko Hozumi, Yasuo Sata, Naohiro Ito, Yoshinori |
author_sort | Fukada, Ippei |
collection | PubMed |
description | BACKGROUND: Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications. Eradication of cancer cells in both breast and lymph nodes has been better associated with improved prognosis than in the breast alone. Even in patients diagnosed as having clinically node-negative cancer before NAC, postoperative pathological examination often shows axillary lymph node metastases. PATIENTS AND METHODS: Of the 771 patients with breast cancer who underwent NAC in the Cancer Institute Hospital between January 2000 and May 2009, 146 patients preoperatively diagnosed as having node-negative breast cancer were retrospectively evaluated. We have made the definition of clinically lymph node-negative (N0) as follows: first, ultrasonography before NAC did not show any lymphadenopathy. Second, a cytological procedure confirmed negative study for each patient when ultrasonography suggested lymphadenopathy. RESULTS: The median observation period was 79.7 months, and the median age of the subjects was 51 years. Pathological examination at the time of the surgery showed lymph node metastases (ypN+) in 46 patients (31.5%). Histological therapeutic effects revealed ypT0/is in 9 patients (6.2%) and ypTinv in 137 (93.8%). Multivariate analysis demonstrated that younger age (49>), large tumor size, NG3, and ypN+ were significant poor prognostic factors for DFS (p = 0.020, p = 0.008, P = 0.022 and p = 0.010, respectively). Moreover, ypN+ was the only significant poor prognostic factor for OS (p = 0.022). The predictive factors of ypN+ in clinically lymph node–negative breast cancer were ypTinv (p = 0.036) and the luminal type (HR+ and HER2-) (p = 0.029). CONCLUSION: The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype. |
format | Online Article Text |
id | pubmed-5025211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-50252112016-09-27 Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer Fukada, Ippei Araki, Kazuhiro Kobayashi, Kokoro Shibayama, Tomoko Takahashi, Shunji Horii, Rie Akiyama, Futoshi Iwase, Takuji Ohno, Shinji Hatake, Kiyohiko Hozumi, Yasuo Sata, Naohiro Ito, Yoshinori PLoS One Research Article BACKGROUND: Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications. Eradication of cancer cells in both breast and lymph nodes has been better associated with improved prognosis than in the breast alone. Even in patients diagnosed as having clinically node-negative cancer before NAC, postoperative pathological examination often shows axillary lymph node metastases. PATIENTS AND METHODS: Of the 771 patients with breast cancer who underwent NAC in the Cancer Institute Hospital between January 2000 and May 2009, 146 patients preoperatively diagnosed as having node-negative breast cancer were retrospectively evaluated. We have made the definition of clinically lymph node-negative (N0) as follows: first, ultrasonography before NAC did not show any lymphadenopathy. Second, a cytological procedure confirmed negative study for each patient when ultrasonography suggested lymphadenopathy. RESULTS: The median observation period was 79.7 months, and the median age of the subjects was 51 years. Pathological examination at the time of the surgery showed lymph node metastases (ypN+) in 46 patients (31.5%). Histological therapeutic effects revealed ypT0/is in 9 patients (6.2%) and ypTinv in 137 (93.8%). Multivariate analysis demonstrated that younger age (49>), large tumor size, NG3, and ypN+ were significant poor prognostic factors for DFS (p = 0.020, p = 0.008, P = 0.022 and p = 0.010, respectively). Moreover, ypN+ was the only significant poor prognostic factor for OS (p = 0.022). The predictive factors of ypN+ in clinically lymph node–negative breast cancer were ypTinv (p = 0.036) and the luminal type (HR+ and HER2-) (p = 0.029). CONCLUSION: The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype. Public Library of Science 2016-09-15 /pmc/articles/PMC5025211/ /pubmed/27631393 http://dx.doi.org/10.1371/journal.pone.0162616 Text en © 2016 Fukada et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Fukada, Ippei Araki, Kazuhiro Kobayashi, Kokoro Shibayama, Tomoko Takahashi, Shunji Horii, Rie Akiyama, Futoshi Iwase, Takuji Ohno, Shinji Hatake, Kiyohiko Hozumi, Yasuo Sata, Naohiro Ito, Yoshinori Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
title | Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
title_full | Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
title_fullStr | Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
title_full_unstemmed | Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
title_short | Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
title_sort | predictive factors and value of ypn+ after neoadjuvant chemotherapy in clinically lymph node-negative breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025211/ https://www.ncbi.nlm.nih.gov/pubmed/27631393 http://dx.doi.org/10.1371/journal.pone.0162616 |
work_keys_str_mv | AT fukadaippei predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT arakikazuhiro predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT kobayashikokoro predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT shibayamatomoko predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT takahashishunji predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT horiirie predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT akiyamafutoshi predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT iwasetakuji predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT ohnoshinji predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT hatakekiyohiko predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT hozumiyasuo predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT satanaohiro predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer AT itoyoshinori predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer |